Novo Nordisk to cut 250 jobs in the United States
Reuters
Published Sep 28, 2018 08:08AM ET
Novo Nordisk to cut 250 jobs in the United States
COPENHAGEN (Reuters) - Denmark's Novo Nordisk (CO:NOVOB) will cut around 250 jobs in the United States, a spokesman told Reuters on Friday, adding the drugmaker would also hire an as-yet undetermined number of staff to new positions.
The diabetes specialist, which employs more than 42,000 people in 79 countries, has seen growth slow due to pricing pressures in the United States, where it makes about half its revenue.
Novo Nordisk will next year have to pay higher rebates on U.S. healthcare scheme Medicare, the spokesman said.
A hundred of the planned staff reductions are from back-office positions in the company's U.S. headquarters in Princeton, New Jersey, while the remaining 150 are among diabetes treatment support positions, he said.
The company said last week it would lay off 400 staff in Denmark and China to divert funding towards investment in biological and technological innovation.
It announced 1,000 job cuts in 2016 as competition among insulin producers increased and prices were squeezed by pharmacy benefit managers who administer drug programs for employers and health plans.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.